Commercialization


  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    3 patent expirations in 2024 and how companies are pivoting

    As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.

    By April 17, 2024
  • glp-1 injector
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where the GLP-1 weight loss market goes will depend on data

    As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.

    By April 15, 2024
  • Pills, medical products in black paper bag in shopping cart on red background.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Cutting pills. Rationing insulin. How Americans struggle to pay for drugs.

    More than 20% of Americans are forgoing prescription medications due to costs, according to a recent survey.

    By April 9, 2024
  • Syringe
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future

    Biosimilars promise market competition for branded biologics, which in theory could drive down prices. But so far, winning market share has been a struggle.

    By April 9, 2024
  • Bernice Bennett, genealogist
    Image attribution tooltip
    Permission granted by Alnylam
    Image attribution tooltip

    Alnylam turns to genealogy to find rare disease patients through family trees

    A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.

    By March 26, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Who’s getting left behind in the weight loss bonanza?

    As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

    By Kelly Bilodeau • March 25, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Orchard sets out to sell world’s priciest gene therapy

    Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.

    By Kristin Jensen • March 20, 2024
  • bottle of Rezdiffra
    Image attribution tooltip
    Courtesy of Madrigal
    Image attribution tooltip

    With historic MASH approval, Madrigal preps for launch and a public offering

    After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.

    By March 20, 2024
  • Bianca Anghelina, CEO, founder, Aily Labs
    Image attribution tooltip
    Permission granted by Aily Labs
    Image attribution tooltip

    Ex-Novartis exec sets out to create ‘Apple of AI’

    Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.

    By Kelly Bilodeau • March 18, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By Jacob Bell • Updated March 8, 2024
  • Thorny issues in pharma
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

    Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

    By Alexandra Pecci • Feb. 26, 2024
  • blue dosing pen for semaglutide
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ozempic for liver disease? Weight loss drugs could have even more to offer

    GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

    By Kelly Bilodeau • Feb. 26, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Ben Fidler • Feb. 23, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • vials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 questions hanging over the Novo-Catalent deal

    As backlash builds for the recently announced matchup, critical questions remain over its impact.

    By Kelly Bilodeau • Feb. 13, 2024
  • syringe dollar sign shadow
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Could Novo, Lilly become first trillion-dollar healthcare companies?

    Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

    By Feb. 2, 2024
  • pill explosion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    10 of our most read articles in 2023

    A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaMore’s most-read articles this year.

    By Dec. 22, 2023
  • blockbuster drugs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What are pharma’s next blockbusters?

    In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

    By Kelly Bilodeau • Dec. 20, 2023
  • Professional photo of Adam Lenkowsky
    Image attribution tooltip
    Permission granted by Adam Lenkowsky
    Image attribution tooltip
    Q&A

    Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

    Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

    By Dec. 12, 2023
  • A sign showing Gilead's logo
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

    Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

    By Alexandra Pecci • Dec. 11, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , Nov. 9, 2023
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    What’s next for COVID dark horse Novavax?

    Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

    By Kelly Bilodeau • Oct. 30, 2023
  • Adele Gulfo Red Jacket header
    Image attribution tooltip
    Permission granted by Sumitomo Pharma America
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Adele Gulfo, a commercialization guru

    With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

    By Karissa Waddick • Oct. 27, 2023
  • a blue megaphone stands out among a crowd of orange megaphones against an orange backdrop
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    3 marketing tips for biotechs emerging from stealth

    In a crowded biotech market, here’s how your company can stand out to investors.

    By Karissa Waddick • Oct. 6, 2023